benralizumab   Click here for help

GtoPdb Ligand ID: 7674

Synonyms: BIW-8405 | Fasenra® | KHK4563 | MEDI-563
Approved drug Immunopharmacology Ligand
benralizumab is an approved drug (FDA (2017), EMA (2018))
Compound class: Antibody
Comment: Benralizumab is a humanized, afucosylated mAb targeting the IL5Rα which is expressed by cells of the eosinophil lineage. The antibody is afucosylated (ie has fucose containing oligosaccharide side-chains removed) to improve structure, stability, and biological function.
Peptide sequence information for this antibody is available from its IMGT/mAb-DB link.
Click here for help
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: benralizumab

No information available.
Summary of Clinical Use Click here for help
In November 2017, the US FDA approved benralizumab as an add-on maintenance treatment for patients with severe eosinophilic phenotype asthma (aged 12 years and older). EMA marketing approval is pending a final decision, with their Committee for Medicinal Products for Human Use (CHMP) having recommended marketing authorisation on 9th November 2017 [3]. Results from Phase 3 clinical trial NCT01914757 are published in [4]. Analysis of trial outcomes show that not all asthma patients will respond to benralizumab, but that in patients with high eosinophil counts (> 300 cells per μL) annual exacerbation rates were significantly reduced. These suggest that targeting the biologic to specific patient populations will provide most clinical benefit. Click here to view's listing of current benralizumab trials.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
This antibody targets the interleukin 5 receptor alpha subunit (IL5RA; IL-5Rα) [5]. Antibody targeting of IL-5Rα depletes eosinophils in lung tissue and bone marrow, thereby reducing eosinophilic inflammation caused by allergen exposure [1,7].